Table 1.
Baseline patient clinical characteristics
| Training cohort | Validation cohort | |
|---|---|---|
| Characteristic | No. (%) or median (range) | No. (%) or median (range) |
| (n=56) | (n=97) | |
| Age, years | 73 (49–89) | 70 (47–90) |
| KPS | 80 (70–90) | 80 (70–90) |
| Chemistry | ||
| PSA, ng/ml | 171 (4.95–4865) | 67.51 (<0.05–3096.37) |
| Hgb, g/dl | 12 (8.4–14.8) | 12.1 (9.2–15.4) |
| ALK, unit/L | 135 (39–2323) | 102 (31–1818) |
| LDH, unit/L | 258 (115–1352) | 204 (87–845) |
| ALB, g/dl | 4 (3.3–4.8) | 4.3 (3.4–5) |
| Primary treatment | ||
| Surgery | 22 (39%) | 43 (44%) |
| Radiation | 22 (39%) | 27 (28%) |
| No primary therapy | 12 (22%) | 27 (28%) |
| Systemic treatment | ||
| Hormone therapy | ||
| 1–2 lines | 25 (45%) | 44 (45%) |
| 3 lines | 15 (27%) | 29 (30%) |
| ≥4 lines | 16 (28%) | 24 (25%) |
| Ketoconazole | 23 (41%) | 44 (45%) |
| Prior chemotherapy | ||
| None | 42 (75%) | 53 (55%) |
| Any | 14 (25%) | 44 (45%) |
| Site of metastatic disease | ||
| Bone | 51 (91%) | 88 (91%) |
| Lymph node | 30 (54%) | 49 (51%) |
| Liver | 7 (12%) | 13 (13%) |
| Lung | 1 (2%) | 13 (13%) |
| Other soft tissue | 4 (7%) | 3 (3%) |
| Deceased | 44 (79%) | 77 (79%) |
| Follow-up (months) | 34 (1–142) | 43.3 (6.8–154) |